Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma
Authors:
- 1 June 2011
- journal article
- Published by Elsevier in Oral Oncology
- Vol. 47 (6) , 510-516
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- CD44, a therapeutic target for metastasising tumoursEuropean Journal of Cancer, 2010
- Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinomaJournal of Cancer Research and Clinical Oncology, 2010
- CD44 variant isoforms in head and neck squamous cell carcinoma progressionThe Laryngoscope, 2009
- Hyaluronan and the Interaction Between CD44 and Epidermal Growth Factor Receptor in Oncogenic Signaling and Chemotherapy Resistance in Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2006
- Inhibition of Hepatocellular Carcinomas in vitro and Hepatic Metastases in vivo in Mice by the Histone Deacetylase Inhibitor HA-ButClinical Cancer Research, 2004
- Signaling Properties of Hyaluronan ReceptorsJournal of Biological Chemistry, 2002
- Hyaluronan Promotes CD44v3-Vav2 Interaction with Grb2-p185HER2 and Induces Rac1 and Ras Signaling during Ovarian Tumor Cell Migration and GrowthJournal of Biological Chemistry, 2001
- Expression of CD44v6 but not E-cadherin or ?-catenin influences prognosis in primary pulmonary adenocarcinomaThe Journal of Pathology, 2000
- Progression in gastric carcinoma relative to the ratio of CD44 epithelial variant transcript to CD44 hematopoietic variant transcriptCancer, 1996
- CD44 isoforms in prognosis of breast cancerThe Lancet, 1995